DelveInsight picked some of the key highlights from Prostate Cancer presented at ASCO21. Have a look.
Abstract# 5059: Cabazitaxel (CBZ) failed to show an edge over the androgen receptor-targeted agent (ARTA) in patients with poor-prognosis mCRPC in the first results from the OSTRICh trial
Cabazitaxel (Jevtana) was approved a decade ago by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen. And since then, Sanofi is also trying to explore the other opportunities for cabazitaxel in prostate cancer and recent findings related to the first results from the phase II/III OSTRICh trial seem not in the favour of the company. This study aims to identify the optimal 2nd line treatment option for patients with a poor prognosis mCRPC with respect to Clinical Benefit Rate (CBR) rate and quality of life. No significant difference in CBR (60% vs. 51%) was established between CBZ and ARTA-treated patients. However, at 12 weeks significantly more CBZ treated patients had no radiological progression (88% vs. 67%), while ≥50% PSA response rates were higher in ARTA-treated patients (23% vs. 49%). Median radiological progression-free survival (rPFS) was 6.0 months in the CBZ arm and 5.8 months in the ARTA, while median overall survival (OS) was 15.3 months and 13.8 months in CBZ and ARTA treated patients, respectively. Also in the safety profile, grade ≥3 adverse events (AEs) occurred in 29% and 15% of patients treated with CBZ and ARTA, respectively.
Get a detailed analysis of the Prostate Cancer Market analysis and forecast here.
